Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 131 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RS+ Clear all
Recruiting Not applicable Interventional

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

NCT06982820
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Prism Training
Device
Lead sponsor
GrayMatters Health Ltd.
Industry
Eligibility
22 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Providence, Rhode Island • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.

NCT06305637
View directory record Official record
Conditions
Tinea Versicolor
Interventions
Ketoconazole Shampoo, 2%, Ketoconazole Shampoo, 2% (Reference Standard), Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 18, 2026, 5:38 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of NVX-CoV2705

NCT07086222
View directory record Official record
Conditions
COVID-19, Sars-CoV-2 Infection
Interventions
NVX-CoV2705, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
50 Years to 65 Years
Enrollment
6,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
99
States / cities
Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Resting-State Functional MRI in Glioma Patients Before and After Surgery

NCT03964909
View directory record Official record
Conditions
Brain Mass, Glioma
Interventions
Functional Magnetic Resonance Imaging, Magnetic Resonance Imaging, Resting State Functional Connectivity Magnetic Resonance Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resistant Starch Wheat for Improved Metabolic Health

NCT03082131
View directory record Official record
Conditions
Gut Microbiota, Metabolism, Metabolic Health
Interventions
Resistant Starch Wheat
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
40 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 18, 2026, 5:38 AM EDT
Terminated Phase 2 Interventional Results available

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

NCT00895245
View directory record Official record
Conditions
Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions
fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, dexamethasone, Functional Living Index-Emesis Questionnaire, Emesis Diary, Radiotherapy
Drug · Other · Behavioral + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Satiety Response of Four Dietary Fibers

NCT01233024
View directory record Official record
Conditions
Healthy
Interventions
Control, Soluble corn fiber, Resistant starch, Fructooligosaccharide, Inulin
Dietary Supplement
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of NVX-CoV2705

NCT07079670
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
NVX-CoV2705
Biological
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 90 Years
Enrollment
676 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
10
States / cities
Phoenix, Arizona • Melrose Park, Illinois • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Recruiting Phase 3 Interventional

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

NCT07391774
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Interventions
Anastrozole, Biospecimen Collection, Bone Scan, Chemotherapy, Computed Tomography, Exemestane, Letrozole, Oncotype DX Breast Cancer Assay, Positron Emission Tomography, Ribociclib Succinate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
203
States / cities
Jonesboro, Arkansas • Auburn, California • Berkeley, California + 169 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed No phase listed Observational Results available

Feasibility - Infinitome

NCT04563767
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Infinitome
Procedure
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 18, 2026, 5:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

NCT02029443
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
Interventions
Acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
8
States / cities
Boston, Massachusetts • New Hyde Park, New York • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Testing the Effectiveness of Relationship Smarts and the Effects of Enhanced Facilitator Training

NCT02831413
View directory record Official record
Conditions
Knowledge, Attitude
Interventions
RS+, Codeacademy
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
Up to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 18, 2026, 5:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fatty Acid Levels and Memory in Breastfed Children

NCT01942434
View directory record Official record
Conditions
Cognitive Development
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Months to 4 Months
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 18, 2026, 5:38 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

NCT01272037
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
Interventions
Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
5,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1435
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently

NCT03496181
View directory record Official record
Conditions
Glioma, Glioma of Brain, Glioma of Spinal Cord
Interventions
Multilingual Aphasia Examination, Language paradigms + RS fMRI, Language paradigms + RS fMRI + one anatomical sequence
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 18, 2026, 5:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

NCT06222593
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Bicalutamide in combination with Sunitinib
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Recruiting Phase 2 Interventional

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

NCT04419649
View directory record Official record
Conditions
Myelodysplastic Syndromes, Cytopenia
Interventions
Elritercept
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
11
States / cities
Hot Springs, Arkansas • Duarte, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Muscle Stimulation for Physical Function During Stem Cell Transplant

NCT04364256
View directory record Official record
Conditions
Autologous Hematopoietic Stem Cell Transplant
Interventions
RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT00364923
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
Pralatrexate Injection
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 18, 2026, 5:38 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy

NCT03560622
View directory record Official record
Conditions
Essential Tremor
Interventions
multi-modality neuroimaging
Device
Lead sponsor
Vibhor Krishna
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 4 Interventional

The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents

NCT00566371
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Insomnia
Interventions
atomoxetine, placebo
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 18, 2026, 5:38 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Speech-Language Treatment With Remotely Supervised Transcranial Direct Current Stimulation in Primary Progressive Aphasia

NCT05901233
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS), Remotely supervised sham tDCS (RS-sham-tDCS), Lexical Retrieval Training (LRT), Video Implemented Script Training in Aphasia (VISTA)
Device · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
San Francisco, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Potato Fiber and Gastrointestinal Function: Phase 3

NCT01964599
View directory record Official record
Conditions
Gastrointestinal Symptoms, Gastrointestinal Transit Time, Stool Frequency
Interventions
PF-RS, PF-RO1, PF-RO2, Control
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 18, 2026, 5:38 AM EDT
Terminated Not applicable Interventional Results available

Y90 Radiation Segmentectomy vs SBRT for HCC

NCT04235660
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Yttrium-90 Radiation Segmentectomy, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 18, 2026, 5:38 AM EDT